Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555582 | 0.88 | LMNA (0.33) | TP53LMNAEGFR | |
| SCHEMBL23555559 | 0.87 | TP53 (0.46) | TP53TRPA1LMNAPDE5ASLC2A1 | |
| SCHEMBL23555570 | 0.87 | PDE5A (0.38) | TP53TRPA1PDE5ASLC2A1EGFR | |
| SCHEMBL25068823 | 0.85 | TP53 (0.39) | TP53TRPA1LMNAPDE5A | |
| SCHEMBL25069135 | 0.84 | TP53 (0.41) | TP53TRPA1LMNAPDE5ASLC2A1 | |
| SCHEMBL23555296 | 0.83 | MAOA (0.33) | TP53TRPA1PDE5ASLC2A1EGFR | |
| SCHEMBL23555314 | 0.81 | TP53 (0.42) | TP53TRPA1LMNAPDE5A | |
| SCHEMBL23555294 | 0.77 | PDE1A (0.41) | LMNAEGFR | |
| SCHEMBL31715265 | 0.77 | PDE5A (0.38) | TP53TRPA1PDE5A | |
| SCHEMBL23555584 | 0.77 | PDE5A (0.40) | PDE5ASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | TP53 499/4885TRPA1 3470/4885LMNA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.